What is in the Neuromuscular Junction Literature?

Area of Science:

• Neurology
• Immunology
• Epidemiology

Background:

• Myasthenia gravis (MG) presents with increasing incidence and mortality, particularly in specific demographics.
• Epidemiological studies reveal disparities in MG outcomes based on age, gender, race, and comorbidities across different regions.
• Understanding the economic burden and clinical features, such as ocular manifestations, is crucial for comprehensive MG management.

Purpose of the Study:

• To review current epidemiological data on myasthenia gravis (MG) incidence and mortality.
• To discuss clinical features, diagnostic approaches, and treatment strategies for MG.
• To highlight recent advancements in MG therapies, including novel biologic agents.

Main Methods:

• Systematic review of epidemiological studies on MG incidence and mortality.
• Analysis of clinical features, diagnostic assays, and treatment outcomes for MG.
• Evaluation of recent therapeutic advancements, including Fc receptor neonatal (FcRN) blockers and monoclonal antibodies.

Main Results:

• Increased incidence and mortality rates of myasthenia gravis (MG) observed globally, with variations across age, gender, and racial groups.
• Light sensitivity is a notable clinical feature, requiring differentiation from thyroid eye disease.
• Diagnostic assays show varying sensitivity and specificity; thymectomy's role in older patients is under consideration.

Conclusions:

• Myasthenia gravis (MG) poses a significant public health challenge with notable epidemiological trends and disparities.
• Current treatment strategies encompass corticosteroids, IVIg, and emerging targeted therapies like FcRN blockers and monoclonal antibodies.
• Continued research into MG pathogenesis and treatment is essential for improving patient outcomes and addressing the economic burden.